BRFH vs KLRS Comparison

Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.